EBITDA: Income before interest, taxes, depreciation and amortization.
Dyne Therapeutics, Inc. (DYN) had EBITDA of $-115.75M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-110.86M |
|
-- |
|
-- |
|
$115.79M |
|
$-115.79M |
|
$4.93M |
|
$-110.86M |
|
$-110.86M |
|
$-110.86M |
|
$-110.86M |
|
$-110.86M |
|
$-110.86M |
|
$-115.79M |
|
|
EBITDA |
$-115.75M |
113.87M |
|
113.87M |
|
$-0.97 |
|
$-0.97 |
|
| Balance Sheet Financials | |
$697.95M |
|
$5.67M |
|
$31.04M |
|
$728.99M |
|
$41.47M |
|
$98.81M |
|
$116.08M |
|
$157.55M |
|
$571.45M |
|
$571.45M |
|
$571.45M |
|
114.34M |
|
| Cash Flow Statement Financials | |
$-200.60M |
|
$8.23M |
|
$242.01M |
|
$437.39M |
|
$487.04M |
|
$49.65M |
|
$23.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.83 |
|
-- |
|
-- |
|
0.15 |
|
0.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-201.64M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.40% |
|
-19.40% |
|
-15.21% |
|
-16.54% |
|
$5.00 |
|
$-1.77 |
|
$-1.76 |
|